No Data
Revenues Working Against China Ever Grand Financial Leasing Group Co., Ltd.'s (HKG:379) Share Price Following 31% Dive
Eg Leasing (00379.HK) plans to sell a property in Minhang District, Shanghai for 6.918 million yuan.
Glory Finance announced on September 20th that eg leasing (00379.HK) has entered into an agreement with the Shanghai-based biological technology limited company (an indirect wholly-owned subsidiary) and the buyer Shanghai Beiolu Biological Materials Co., Ltd. Seller agrees to sell and buyer agrees to purchase the property, with a total price of RMB 6.918 million. "Property" refers to Building 6, Unit 203, No. 188 Xinjunhuan Road, Minhang District, Shanghai, China.
EG LEASING: INTERIM REPORT 2024
Eg Leasing (00379.HK) and its subsidiary received a civil complaint from the court.
GrontoSeptember 13th, Eg Leasing (00379.HK) announced that the board of directors recently learned that the company's wholly-owned subsidiary, Hong Kong Eg Capital Limited, has received a civil complaint issued by the Fourth Intermediate People's Court of Peking. The court has accepted a lawsuit filed by Beijing Eg (as the plaintiff) against Hong Kong Eg (as the defendant) regarding capital injection. According to the complaint, the plaintiff requests the defendant to pay a capital injection amount of $22,610,000, its related interest, and all litigation costs incurred by the defendant in this case. As of the date of this announcement, Zhongan (another entity of Beijing Eg)
Express News | China Ever Grand Financial Leasing - Complaint Requesting Unit to Pay Capital Injection Amount of US$22.61 Mln
eg leasing (00379.HK) mid-term continuous operation business income 47 million Hong Kong dollars, a year-on-year increase of 129.5%
Eg Leasing (00379.HK) announced on August 22 that for the six months ended June 30, 2024, the group's operating income from continued operations was 47 million Hong Kong dollars, an increase of 129.5% year-on-year. The net loss from continuing operations during the period was 43.6 million Hong Kong dollars, an increase of 100.8% from the corresponding period's 21.7 million Hong Kong dollars. The loss per share from both continuing and non-continuing operations was 2.58 Hong Kong cents. The increase in operating income from continuing operations was mainly due to the increase in sales of traditional Chinese medicine products and proprietary health products.
No Data
No Data